This page lists all known medications that could potentially lead to 'Posterior uveitis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

September 28, 2010 — The US Food and Drug Administration (FDA) has approved a dexamethasone 0.7 mg intravitreal implant (Ozurdex; Allergan, Inc) for the treatment of noninfectious ocular inflammation ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A phase 3 trial of Durasert 3-year ...

An open-label clinical trial including seven patients (12 eyes) with posterior uveitis refractory to conventional treatment regimens with corticosteroids and at least one immunosuppressive agent.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Durasert, a 3-year treatment for ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners ...

Twenty-one patients with syphilitic posterior uveitis were investigated retrospectively to study the disease spectrum, associations with neurosyphilis, and therapeutic implications. Ophthalmologic ...

ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners ...

It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly. Testing for myeloid ...